AllAnalyst Report
logoMorningstarOctober 03, 2024

Repligen Corporation: Repligen: Initiating Coverage With Narrow Moat Rating and $180 FVE; Shares Undervalued

Symbols
RGEN
Sector(s)
Healthcare
Rating
Current Price
$136.71
Fair Value
Economic Moat
Stewardship
Summary

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while ch

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Upgrade